Andere talen Syncona Limited

Aandelen

BACT

GG00B8P59C08

Holdingvennootschappen

Beurs gesloten - London S.E. Andere beurzen 17:35:13 12-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
103,00 ^GBX	+0,59%		+0,98%	-16,53%

06/12	Syncona verheugt zich over positieve testgegevens voor nieuw geneesmiddel van Beacon Therapeutics	AN
19/11	Syncona Limited kondigt het terugtreden aan van Gian Piero Reverberi als lid van de Auditcommissie van de Raad van Bestuur	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Syncona hails positive trial data for new Beacon Therapeutics drug	06/12
Syncona : Beacon Therapeutics Announces Positive 3 Month Data from Phase 2 DAWN Trial of laru zova (AGTC 501) in Patients with X Linked Retinitis Pigmentosa (XLRP)	06/12
Syncona : Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program	03/12
Syncona Limited Announces Step Down of Gian Piero Reverberi as Member of Its Board Audit Committee	19/11
Syncona : OMass Therapeutics Appoints Professor Steven Charlton as Chief Scientific Officer	15/11
Syncona net assets values down; announces new portfolio firm Slingshot	14/11
Syncona Launches Early-stage Life Science Accelerator Company	14/11
Syncona Posts Bigger Fiscal H1 Loss; Total Investment Income Rise	14/11
Earnings Flash (SYNC.L) SYNCONA Posts Fiscal H1 Loss GBX-11.61	14/11
Syncona : Slingshot Therapeutics launches with its first programme and £12.5 million to accelerate early-stage drug development	14/11
Syncona : Interim Results for the period ending 30 September 2024	14/11
Syncona Limited Reports Earnings Results for the Half Year Ended September 30, 2024	14/11
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023.	14/11
Syncona's Autolus wins FDA approval for aggressive leukaemia therapy	11/11
Syncona : Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel obe cel) for adults with relapsed/refractory B cell acute lymphoblastic leukemia (r/r B ALL)	08/11
Syncona : Kesmalea Therapeutics Appoints Robert Johnson as CEO To Lead Development of New Class of Oral, CNS Penetrant Protein Degraders	07/11
Syncona : Spur Therapeutics Publishes Preclinical Proof of Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)	31/10
Syncona : Investor Webinar	30/10
Syncona : Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting	30/10
Syncona celebrates investee's positive trial data on Gaucher disease	23/10
Syncona : Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses	22/10
Strix lauds "milestone"; Quartix to meet expectations	15/10
Syncona makes further investment in Purespring Therapeutics	09/10
Syncona's Portfolio Company Purespring Therapeutics Raises GBP80 Million via Series B Financing	09/10
Syncona : Mosaic Therapeutics appoints Dr Barry Davies as CSO	07/10

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Syncona Limited

Aandelen

BACT

GG00B8P59C08

Holdingvennootschappen

Andere talen

Filters